Company Profile

Bugworks Research India Pvt. Ltd.


About the Organization


BUGWORKS aims to discover novel biopharmaceutical assets for the treatment of antibiotic resistant bacterial infections. BUGWORKS has unlocked a new paradigm to discover novel antibiotics. BUWORKS is a spinout from Cellworks Group Inc., a widely recognized leader in the use of Systems Biology approaches to designing novel combinations for cancer & inflammation. BUGWORKS is led by a team with greater than 125 years of combined experience in infection research. Using systems biology, structural biology and medicinal chemistry, we have developed a novel methodology to mitigate efflux mediated drug resistance a key barrier to overcome for developing the next generation of successful antibiotics. Bugworks was adjudged the “Emerging Company of the Year” in the Biopharma-Healthcare segment at the 2015 Bangalore BIO event & received “SME Excellence Award in Innovation” in Pharmaceuticals sector by Karnataka State Small & Medium Business Owners Association for 2015. Bugworks has won major competitive non-dilutive grants from the DBT, Govt. of India & UK-BBSRC. During their tenure within Cellworks, the same team won grants from the Wellcome Trust, EU-FP07 & DBT, Govt. of India.

Year of establishment



Name and contact details of Chairperson/Managing director
a. Name


b. Designation:




Key areas of operations


Antibiotic Discovery Biomedical Devices

Contact address


CCAMP, NCBS Campus, GKVK, Hebbal Bengaluru 560065



Other Information


Our current portfolio of assets targeting hospital-associated infections center around two major themes: i discovery of novel drugs that counter efflux mediated drug resistance and ii discovery of device surface applicants that prevent bacterial biofilms a source of chronic drug resistant infections in hospital settings. In the first asset class, we combine the prowess of structural biology, computational chemistry and medicinal chemistry to obviate efflux-mediated resistance in bacteria, resulting in the discovery of novel antibiotics. Our Lead chemical series kills a broad spectrum of pathogens via a novel mechanism potent on multi-drug resistant clinical isolates of E. coli including ESBLs, NDM-1 , S. aureus including MRSA , K. pneumoniae including KPCs , A. bauminii, P. aeruginosa, E. faecalis including VRE . The above six species collectively known as ESKAPE pathogens account for more than 90 of hospital associated infections worldwide.